Andrew Stewart Plump Sells 116,191 Shares of Takeda Pharmaceutical (NYSE:TAK) Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Andrew Plump sold 116,191 shares of the company’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $18.49, for a total value of $2,148,371.59. Following the transaction, the insider directly owned 145,465 shares in the company, valued at approximately $2,689,647.85. The trade was a 44.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Andrew Stewart Plump also recently made the following trade(s):

• On Wednesday, August 19th, Andrew Plump sold 19,651 shares of Takeda Pharmaceutical stock. The stock was sold at an average price of $18.49, for a total value of $363,346.99.
• On Monday, August 10th, Andrew Plump sold 165,393 shares of Takeda Pharmaceutical stock. The stock was sold at an average price of $17.10, for a total value of $2,828,220.30.

Takeda Pharmaceutical Price Performance

TAK opened at $18.46 on Friday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.62 and a current ratio of 1.14. The stock has a market capitalization of $59.15 billion, a P/E ratio of 54.29 and a beta of -0.07. The company’s 50-day simple moving average is $17.32 and its two-hundred day simple moving average is $17.21. Takeda Pharmaceutical Co. has a 52-week low of $12.99 and a 52-week high of $18.90.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings results on Thursday, July 30th. The company reported $0.95 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.54. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. The firm had revenue of $7.50 billion for the quarter, compared to the consensus estimate of $7.13 billion. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. As a group, analysts predict that Takeda Pharmaceutical Co. will post 1.54 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Weiss Ratings downgraded Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, July 30th. Finally, Zacks Research raised Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy”.

Institutional Trading of Takeda Pharmaceutical

Institutional investors have recently made changes to their positions in the business. Angeles Wealth Management LLC boosted its stake in Takeda Pharmaceutical by 31.5% during the second quarter. Angeles Wealth Management LLC now owns 17,800 shares of the company’s stock valued at $289,000 after buying an additional 4,265 shares during the last quarter. Concurrent Investment Advisors LLC bought a new stake in Takeda Pharmaceutical in the 2nd quarter worth approximately $191,000. Natural Investments LLC raised its holdings in shares of Takeda Pharmaceutical by 3.6% during the 2nd quarter. Natural Investments LLC now owns 17,230 shares of the company’s stock worth $276,000 after acquiring an additional 596 shares in the last quarter. Valeo Financial Advisors LLC purchased a new stake in shares of Takeda Pharmaceutical during the 2nd quarter worth approximately $163,000. Finally, GAMMA Investing LLC boosted its position in shares of Takeda Pharmaceutical by 10.7% during the 2nd quarter. GAMMA Investing LLC now owns 13,837 shares of the company’s stock valued at $222,000 after acquiring an additional 1,338 shares during the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.